HEC CJ PHARM (1558.HK)
- Previous Close
13.160 - Open
13.240 - Bid 13.400 x --
- Ask 13.440 x --
- Day's Range
13.060 - 13.460 - 52 Week Range
7.920 - 13.520 - Volume
1,627,800 - Avg. Volume
5,656,770 - Market Cap (intraday)
11.792B - Beta (5Y Monthly) 0.03
- PE Ratio (TTM)
22.33 - EPS (TTM)
0.600 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 29, 2020
- 1y Target Est
14.01
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. engages in the development, manufacturing, and sale of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic, and cardiovascular diseases in the People's Republic of China. It manufactures and sells active pharmaceutical ingredients and drugs; researches and develops pharmaceutical products and medical devices, as well as biotechnology; and provides marketing and medical consulting services. The company's product portfolio includes Kewei, Oumeining, Xinhaining, Ertongshu, and Xining. It sells its products to hospitals and medical institutions through a network of distributors. The company was formerly known as Yichang Changjiang Pharmaceutical Company Limited and changed its name to YiChang HEC ChangJiang Pharmaceutical Co., Ltd. in May 2015. The company was incorporated in 2001 and is based in Yichang, China.
www.hec-changjiang.com4,861
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 1558.HK
View MorePerformance Overview: 1558.HK
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1558.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1558.HK
View MoreValuation Measures
Market Cap
11.58B
Enterprise Value
12.48B
Trailing P/E
22.08
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.87
Price/Book (mrq)
1.26
Enterprise Value/Revenue
3.09
Enterprise Value/EBITDA
10.75
Financial Highlights
Profitability and Income Statement
Profit Margin
12.96%
Return on Assets (ttm)
3.32%
Return on Equity (ttm)
5.87%
Revenue (ttm)
3.72B
Net Income Avi to Common (ttm)
482.71M
Diluted EPS (ttm)
0.600
Balance Sheet and Cash Flow
Total Cash (mrq)
1.41B
Total Debt/Equity (mrq)
26.27%
Levered Free Cash Flow (ttm)
-93.31M